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Introduction
Pseudoxanthoma elasticum (PXE, OMIM 264800) in humans 
is defined by dystrophic and progressive mineralization of elastic 
fibers in cutaneous, ocular and vascular tissues. This condition 
derives from loss-of-function mutations in the human ABCC6 
and mouse Abcc6 genes (alias Multidrug Resistance Protein 6 or 
MRP6).1-3 ABCC6 is primarily expressed in liver and has a much 
reduced but measurable expression in kidney, intestine and the 
retina. To a much lesser extent, ABCC6 is detectable in many 
other tissues including lung, skin and vessel walls.4-7 ABCC6 is 
a member of the large ATP-binding cassette (ABC) gene sub-
family C, which uses ATP hydrolysis to drive organic anion 
transport across cellular membranes. ABCC6 actively transports 
glutathione conjugates,7 but as yet, the specific substrate for this 
transporter, and hence the contributing factor to PXE, remains 
unknown. Importantly, the encoded transmembrane protein 
pseudoxanthoma elasticum (pXe) is a heritable disease characterized by calcified elastic fibers in cutaneous, ocular 
and vascular tissues. pXe is caused by mutations in ABCC6, which encodes a protein of the Atp-driven organic anion 
transporter family. the inability of this transporter to secrete its substrate into the circulation is the likely cause of pXe. 
Vitamin K plays a role in the regulation of mineralization processes as a co-factor in the carboxylation of calcification 
inhibitors such as Matrix Gla protein (MGp). Vitamin K precursor or a conjugated form has been proposed as potential 
substrate(s) for ABCC6. We investigated whether an enriched diet of vitamin K1 or vitamin K2 (MK4) could stop or slow 
the disease progression in Abcc6-/- mice. Abcc6-/- mice were placed on a diet of either vitamin K1 or MK4 at 5 or 100 mg/
kg at prenatal, 3 weeks or 3 months of age. Disease progression was quantified by measuring the calcium content of 
one side of the mouse muzzle skin and histological staining for calcium of the opposing side. Raising the vitamin K1 
or MK4 content of the diet increased the concentration of circulating MK4 in the serum. However, this increase did not 
significantly affect the MGp carboxylation status or reduce its abnormal abundance, the total calcium content or the 
pathologic calcification in the whiskers of the 3 treatment groups compared to controls. our findings showed that raising 
the dietary intake of vitamin K1 or MK4 was not beneficial in the treatment of pXe and suggested that the availability of 
vitamin K may not be a limiting factor in this pathology.
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is located in the basolateral membrane of hepatic cells and the 
basal lateral membrane of the proximal kidney tubules where 
the inability of this transporter to secrete its unknown substrate 
towards the circulation is hypothesized to be the cause of the PXE 
disease progression and describes PXE as a metabolic disorder.8
Control of bone mineralization and calcification of soft tissues 
is a highly regulated process, requiring a fine balance between 
inhibitors and promoters at both the circulatory and local 
level.9,10 Among the primary local regulators of mineralization, 
Matrix Gla Protein (MGP) and osteocalcin (OC) are reliant on 
carboxylation for their activation and function.10,11 Gheduzzi et 
al. described PXE patients with a lower serum concentration of 
MGP and a higher ratio of under carboxylated MGP than in 
controls. In addition, this under carboxylated MGP co-localized 
with calcified elastic fibers.10 Uitto et al. also found the con-
nective tissue capsule surrounding the vibrissae of the Abcc6-/- 
mouse whisker was calcified and contained exclusively under 
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we investigate whether a high dietary intake of vitamin K could be 
beneficial to PXE patients. For this purpose, we used an Abcc6-/- 
mouse model of the disease.23 We aimed to discover whether the 
provision of a diet enriched with two active forms of vitamin 
K (K1 and MK4) could compensate any negative effects of the 
Abcc6 knockout on the development of mineralization. Secondly, 
we investigated whether the lack of Abcc6 had any effect on the 
absorption, metabolism or distribution of vitamin K compared to 
WT controls under normal diet conditions.
Results
Progression of the PXE phenotype. In order to determine the 
optimum time range to conduct our experiments to stop or mini-
mize the progression of calcification, we precisely quantified the 
mineralization of the whisker over the life span of Abcc6-/- mice 
(approximately 28–32 months). We established that within the 
period from 3 weeks to approximately 6 months of age there is 
a near-exponential rate of deposition of calcium in the vibrissae. 
This rate of calcification slows after 6 months of age and reaches 
a gently sloping plateau thereafter up to the natural demise of the 
animal (Fig. 1).
Effects of vitamin K supplementation. The diet schedule of 5 
mg (low dose) or 100 mg/kg (high dose) vitamin K1 or vitamin 
MK4 corresponded to a 5-fold and 100-fold increase respectively 
in vitamin K1 above normal diet. For the MK4 supplementa-
tion, the actual increase could only estimated to be in the similar 
range of 5 to 100-fold because this form of vitamin K2 can be 
readily converted in vivo from vitamin K1, which is naturally 
present as traces in the animal chow and can also be synthesized 
by extra-hepatic tissues.26 However, given the large increase in 
serum concentration of MK4 in mice fed the MK4 enriched diet, 
the diet supplementation in vitamin MK4 produced the expected 
boost in the circulation.
Interestingly, mice fed with both concentrations of the 
enriched vitamin K1 diet showed no overt adverse effects on 
physiology or behavior, whereas Abcc6-/- mice fed with a high 
dose of MK4 had marked liver discoloration, with small dis-
tinct lesions on the liver surface. These mice also showed an 
apparent increased propensity to blood clotting observed upon 
blood withdrawal. Approximately 50% of the WT mice fed the 
enriched high dose MK4 diet also had areas of hair loss and 
skin lesions consistent with increased scratching. However, no 
change in the gross appearance of their liver was observed.
Vitamin K1 or MK4 enriched diets do not affect tissue min-
eralization in Abcc6-/- mice. Neither of the vitamin K enriched 
diets or treatment times had any effect on the total calcium con-
tent of the vibrissae tissue for WT mice, which contained very 
low levels of calcium (Figs. 2 and 3). In contrast to WT mice, 
Abcc6-/- mice fed with the normal diet up to 5 months of age had 
significantly elevated total calcium content levels in the vibrissae 
area. Importantly, we measured no significant change in the total 
calcium content of the vibrissae between Abcc6-/- mice fed on a 
normal diet or the vitamin K1 enriched diet for any of the three 
treatment groups (in utero, from pre-onset or from post-onset 
of phenotype). In each case, we measured significant increases 
carboxylated MGP.12 Vitamin K is an essential component in the 
post-translational carboxylation of glutamate residues (Glu) in 
these inhibitor proteins. The reduced form of vitamin K acts as 
cofactor in the conversion of the Glu (inactive) form to the Gla 
form (γ-carboxyglutamate). With this in mind, it was recently 
hypothesized that a vitamin K precursor or a conjugated form 
was the potential substrate(s) for ABCC6.13
It is also known that PXE patients have low serum vitamin 
K levels and it was proposed that this low level might result in 
insufficient carboxylation of the circulating inhibitors of miner-
alization thus leading to mineral deposition in peripheral tissues. 
A subgroup of mutations in the gamma-glutamyl carboxylase—
gene (GGCX ) that encodes an enzyme essential in the carboxyl-
ation of Gla proteins results in a PXE-like phenotype and some 
coagulation factor deficiency. Mutations in the vitamin K 2,3 
epoxide reductase (VKORC1) however, only result in deficien-
cies in the vitamin K dependent clotting factors (II, VII, IX, 
X).14 The link between vitamin K, vitamin K-dependent (VKD) 
proteins and PXE or PXE-like phenotypes has been previously 
discussed in references 15 and 16.
Vitamin K is a group of lipophilic, hydrophobic compounds. 
Of the two forms of naturally occurring vitamin K, vitamin 
K1- phylloquinone (phytomenadione), is the primary source for 
humans. Obtained from the leafy green plants and vegetables, it 
is poorly absorbed but has a high hepatic concentration. Vitamin 
K2 or menaquinones, are more unsaturated and have a variable 
number of isoprenyl groups (four in the case of MK4). There is 
an increased concentration of the menaquinones in extra-hepatic 
tissue compared to vitamin K1. MK4 is synthesized by mam-
malian tissues and additionally converted from vitamin K1.17,18 
Some functions of the menaquinones and vitamin K1 appear 
interchangeable, notably in the activation of clotting factors 
but others such as bone resorption are more specific to the par-
ticular chemical structure of the type of vitamin K. However, 
one should note that depending on the type of vitamin K being 
tested, either phylloquinone or menaquinone, the efficacy of 
these compounds seems to depend on the specific circumstances 
being investigated.19-21 Of particular relevance to this investiga-
tion are studies using a rat model of arterial calcification. Here 
vitamin K1 and vitamin K2 (MK4) were shown to be equally 
effective in reversing the warfarin-induced calcification, thus 
implying interchangeable roles for these two compounds within 
this particular model.22
The phenotype of the Abcc6-/- mice we used has previously 
been described in reference 23. Two Abcc6 knockout mice essen-
tially recapitulate the PXE disease progression with mineraliza-
tion of the skin, the Bruch’s membrane of the eye and small size 
arteries.23,24 One notable feature of these mice, and of particular 
interest in this study, is the calcification of the vibrissae’s capsule 
in the whiskers, the connective tissue capsule surrounding the 
hair follicle.23,24 The calcification of this tissue (not present in 
humans) occurs at approximately 5 weeks of age and is reported 
to be progressive23 and quantifiable and thus serves as a marker of 
disease progression.25
To address the hypothesis that a vitamin-K dependent calcifi-
cation inhibition process plays a role in the pathology of PXE,15,16 
1812 Cell Cycle Volume 10 Issue 11
circulating levels of vitamin K1 and MK4 in the serum of mice 
fed with either a normal diet, or vitamin K1 or vitamin MK4 low 
and high dose enriched diets. Baseline vitamin K1 serum content 
was defined from WT mice fed a normal diet. In both the control 
WT pre-onset and 3 months feeding groups fed with a high dose 
of vitamin K1, we detected a significant increase in vitamin K1 
levels above baseline. However, we were unable to detect signifi-
cant increases in vitamin K1 from WT mice fed on the low dose 
diets, thus indicating that 5 mg/kg was ineffective at significantly 
raising the concentration of circulating vitamin K1 in these ani-
mals (Fig. 5). Although we saw some increase in the levels of vita-
min K1 circulating in the serum of Abcc6-/- mice fed with the high 
dose, 100 mg/kg, vitamin K1 at pre-onset and the in utero group, 
it was not a statistically significant increase (Fig. 5). Moreover, in 
comparison to paired WT controls, the Abcc6-/- mice in the pre-
onset group fed the high dose diet had significantly less vitamin 
K1 circulating thus indicating that Abcc6 could play some role in 
vitamin K1 absorption or circulation (Fig. 5).
Our studies also showed interesting differences in the levels 
of circulating MK4 in mice fed exclusively with normal or vita-
min K1 enriched diets. In mice fed a normal diet, we measured 
significantly more circulating MK4 in WT mice than in Abcc6-/-. 
in calcium deposition between WT and Abcc6-/- mice (Fig. 2). 
Additionally, we measured no significant difference in total cal-
cium content in muzzle tissue taken from Abcc6-/- mice fed exclu-
sively on a normal diet or fed with the high or low dose MK4 
enriched diet. In all the MK4 dietary regimes tested, we saw sig-
nificant increases in total calcium content of the muzzle tissue in 
Abcc6-/- mice compared with WT (Fig. 3).
To confirm the location and extent of the calcium deposition 
within the whiskers, we performed Alizarin red S staining on par-
affin sections of the tissue. As expected, no staining was observed 
in WT mice fed with either the normal or vitamin K enriched 
diets. In contrast, Abcc6-/- mice fed on a normal diet had signifi-
cantly elevated Alizarin red staining in the vibrissae consistent 
with calcium deposition within the capsule. Moreover, no change 
in the amount or location of the calcium deposition between the 
normal diet and any of the enriched diet fed mice was observed 
(Fig. 4). The histological staining was consistent with the calcifi-
cation quantifications indicating that oral administration of high 
dosage of either vitamin K1 or vitamin MK4 has no effect on 
mineral deposition in the vibrissae of an Abcc6-/- mouse.
A diet enriched in vitamin K1 lead to elevated circulating 
levels of vitamin K1 and MK4. Using HPLC-MS, we analyzed 
Figure 1. total calcium content in the muzzle skin of aging Wt and Abcc6-/- mice. Calcium deposition in the Abcc6-/- mice was quantified by a colorimet-
ric assay described in the Material and Methods section. Calcification initially increases with age with the significant increases occurring after  
3 months of age. the largest increase in mineralization occurs between 3 weeks and 6 months. At around 12 months of age there is a gentle plateau in 
the rate of mineralization with no statistical increase measured throughout the rest of the ~28–30 months life span of the mice.
www.landesbioscience.com Cell Cycle 1813
detected very low levels of circulating MK4 in the Abcc6-/- in 
utero group fed with the high, 100 mg/kg, vitamin K2 diet and 
at present we are unable to explain this result, though one may 
suggest an adaptation of the mice to a greater influx of the vita-
min from the diet over a longer period of time.
The carboxylation status of MGP and OC in the capsule of 
the vibrissae. We found no change in the carboxylation status of 
MGP in the capsule surrounding the vibrissae. The ucMGP was 
found mainly associated with the calcified area. MGP detected 
with an antibody that targets both under-carboxylated and car-
boxylated MGP was found also throughout the calcified regions 
of the capsule. We found no major association between OC and 
the calcification in the vibrissae of Abcc6-/- mice. Furthermore, the 
diet, whether normal or enriched with vitamin K, produced no vis-
ible change in OC levels in the vibrissae’s capsule (data not shown).
Blood chemistry. We found no significant difference in the 
blood chemistry between mice fed either a normal diet or the 
vitamin K1 5 or 100 mg/kg diets for all parameters. Ion levels, 
blood glucose, pH etc., were all within normal physiological 
Similarly in mice fed the high dose vitamin K1 diet, WT mice had 
significantly more circulating MK4 than Abcc6-/- mice (Fig. 6). 
In general, in Abcc6-/- mice fed the enriched vitamin K1 diet, we 
were able to measure an increase in circulating MK4 compared 
to Abcc6-/- mice fed on a normal diet. However, this increase was 
not statistically significant (Fig. 6).
A vitamin MK4-enriched diet boost MK4 circulating levels. 
Serum analysis from WT mice fed on a diet enriched with 
5 mg/kg of vitamin MK4 showed significantly increased levels 
of this compound indicating that this dosage was quite effec-
tive in raising the serum levels of MK4. In Abcc6-/- mice how-
ever, the increase in circulating MK4 from mice fed on the low 
dose MK4 diet was not significant. In contrast, the Abcc6-/- mice 
fed with the high dose of MK4 in both the pre- and post-onset 
groups had significantly increased levels of circulating MK4 com-
pared to WT and Abcc6-/- mice fed a normal diet. It is impor-
tant to note that this data indicates that in Abcc6-/- mice, MK4 
was available to the periphery in quantities greater than seen 
in WT or Abcc6-/- animals on a normal diet (Fig. 7). Also, we 
Figure 2. Calcification in the whole muzzle skin of mice fed diets enriched with 5 or 100 mg/kg of vitamin K1. No significant difference in calcium 
deposition was observed between the Abcc6-/- mice on normal or vitamin K1 enriched diets, with all Abcc6-/- mice having significantly more mineraliza-
tion than Wt controls. Mouse diets are described as ‘pre-onset’ of phenotype consist of mice fed on the diet from ~day 21 for 16 weeks. ‘post-onset’ 
corresponds to mice fed from ~3 months of age (already possessing the calcification phenotype) for 12 weeks. In utero mouse samples were taken 
from mice which, when in utero, had mothers fed on the relevant diet and continued with the diet, through breast feeding and weaning up until 5 
months of age.
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carboxylated MGP levels at the site of the calcium deposit.22 This 
and the fact that PXE is a metabolic disease, and that a PXE-like 
disease with a similar phenotype is related to vitamin K, has led to 
the hypothesis of ABCC6 as a transporter of vitamin K.13 The aim 
of this study was therefore to investigate whether a large increase 
in vitamin K from the diet could raise the peripheral availability 
of vitamin K and thus have an effect on the calcification process 
in Abcc6-/- mice, an animal model for PXE.
The link between vitamin K and mineralization is now well 
established,31 but due to the nature of vitamin K being a family of 
chemically related compounds with differing chemical structures, 
their respective activities are not necessarily fully understood. The 
type and dosage of vitamin K can also have vastly different effects 
on the model being studied. For example the Rotterdam study, a 
prospective, population-based cohort study, has shown that mena-
quinone but not phylloquinone is important in preventing vascu-
lar calcification and coronary heart disease.32 However, studies in 
rats using plasma prothrombin levels as a marker for vitamin K 
status have shown that low dietary doses of phylloquinone is more 
effective at maintaining vitamin K status than menaquinone 
levels as seen with the control normal diet fed mice (data not 
shown).
Discussion
Mutations in ABCC6 alone cannot explain the high phenotypic 
variation in PXE patients.27,28 More emphasis is now being placed 
on environmental factors such as: diet, smoking and hormone bal-
ance to explain the complexity of the intra/inter familial pheno-
typic variation.29,30 Although PXE patients have no deficiency in 
the vitamin K-dependent clotting factors synthesized within the 
liver, which incidentally suggest an adequate supply of vitamin K 
in this tissue, they have very low concentrations of this vitamin 
in the periphery.16 Additional work by Vanakker et al. established 
a strong link between low serum concentration of vitamin K and 
decreased carboxylation of inhibitors of the mineralization pro-
cess in the plasma and serum such as MGP and OC.16 Studies in 
rats have also shown that supplementation with vitamin K can 
reverse arterial calcification induced by warfarin, a known inhibi-
tor of the vitamin K cycle. This is probably due to an increase in 
Figure 3. Muzzle skin calcification of mice fed diets enriched with 5 or 100 mg/kg of vitamin MK4. No significant difference in calcium deposition was 
observed between the Abcc6-/- mice on normal or vitamin MK4 enriched diets with all Abcc6-/- mice having significantly more mineralization than Wt 
controls. Mouse diets are described as ‘pre-onset’ of phenotype consist of mice fed on the diet from ~day 21 for 16 weeks. ‘post-onset’ corresponds to 
mice fed from ~3 months of age (already possessing the calcification phenotype) for 12 weeks. In utero mouse samples were taken from mice which, 
when in utero, had mothers fed on the relevant diet and continued with the diet, through breast feeding and weaning up until 5 months of age.
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introduced by choice and depth of sections to analyze. This 
method is very sensitive as we were able to reliably detect a signifi-
cant increase in amount of calcification between groups of Abcc6-/- 
mice aged 4 weeks apart. Using total calcium quantification, 
we confirmed our findings initially obtained with Alizarin Red 
S staining and found no effect of any of the feeding regimes of 
either vitamin K1 or MK4 on total calcium content of the muzzle 
tissue in Abcc6-/- mice (Figs. 2 and 3). In addition, we compared 
kidney tissue sections from vitamin K treated Abcc6-/- mice and 
found typical levels of calcification (data not shown).23,33
Because of the lack of effect of vitamin K supplementa-
tion on the progression and severity of the mineralization phe-
notype of Abcc6-/- mice, we verified how much of the dietary 
increase in vitamin K1 and MK4 was actually absorbed, 
(MK9), but at higher doses the activity is the same.21 For this rea-
son we designed our experiments using two types of commercially 
available vitamin K (K1 and MK4) to increase the probability of 
measuring an effect of this vitamin on the disease progression.
One advantage of using the Abcc6-/- mouse model is the con-
sistency of its biomarkers of disease progression. The level of cal-
cification in the bulb of the vibrissae between the Abcc6-/- mice is 
very consistent and also easily measurable. When compared with 
staining typically observed in Abcc6-/- mice fed with a control 
diet, we found no alteration in the staining patterns around the 
bulb of the vibrissae in any of the vitamin K treatment groups 
(Fig. 4). Analyzing the total calcium content of the muzzle tis-
sue negates the need for time-consuming morphometric analy-
sis of stained tissue sections and additionally removes any bias 
Figure 4. Histological evaluation of calcification in the vibrissae of Wt and Abcc6-/- mice. Connective tissue calcium deposition was observed with 
Alizarin S Red staining in mice fed with either normal diet, or diet enriched in vitamin K1 or vitamin MK4 at 5 or 100 mg/kg. Sections of the muzzle skin 
were taken from each mouse from all mouse diet treatment groups. Mouse diets are described as ‘pre-onset’ of phenotype consist of mice fed with 
the diet from ~day 21 for 16 weeks. ‘post-onset’ corresponds to mice fed from ~3 months of age (already possessing the calcification phenotype) for 
12 weeks. In utero mouse samples were taken from mice which, when in utero, had mothers fed with the relevant diet and continued with the diet, 
through breast feeding and weaning up until 5 months of age. Size of hair follicle and depth of sections cut into the tissue were used as a guide to 
match relevant Wt and Abcc6-/- sections. We observed no difference in placement or extent of calcium deposition. the same amount of staining oc-
curred in the capsule surrounding the vibrissae in the whiskers in the Abcc6-/- mice fed control or either of the two vitamin K enriched diets.
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This discrepancy in circulating serum K1 levels between the two 
strains indicates that in Abcc6-/- mice the vitamin K1 is absorbed 
from the chow and re-circulated into the blood stream but with 
less efficiency than in WT.
In our mice treated with the high dose diet of MK4, we mea-
sured no difference between circulating MK4 in WT or Abcc6-/- 
mice indicating a good absorbance of this form of vitamin K 
from the diet. Additionally, these data show that elevated levels 
of vitamin K1 and MK4 were effectively absorbed from the diet 
and are able to pass into the circulation in WT and Abcc6-/- ani-
mals, and thus potentially available to peripheral tissues for the 
activation of MGP by carboxylation. We detected an increase in 
total MGP in the vibrissae of Abcc6-/- mice in association with 
areas of mineralization as expected.25 However, large proportion 
of this MGP remained un-carboxylated despite the increase in 
the availability of the vitamin K co-factors. The increased level of 
total MGP in association with calcified regions in the whiskers, 
compared to the levels observed in the WT mice, suggested a 
heightened synthesis of MGP perhaps as a compensatory mecha-
nism. Nevertheless, this increase appears ineffectual in over-
coming the calcium deposition because the vast majority of this 
overproduced MGP is not carboxylated.
passed into the circulation and was available to peripheral tis-
sues. The reduction in circulating vitamin K1 levels measured in 
human PXE patients16 was not reproduced in our mouse model. 
We measured no significant difference (Fig. 5) in the serum base-
line concentration of circulating vitamin K1 in the Abcc6-/- and 
WT animals fed with a normal diet, with both strains of mice 
having a low concentration of this vitamin K form and therefore 
providing the first indication that a reduced peripheral vitamin 
K1 concentration is not a factor in the mouse mineralization phe-
notype. However, we did measure a significantly lower baseline 
circulating level of MK4 in the Abcc6-/- mice compared to WT. 
This not only indicates less availability of this form of vitamin 
K for carboxylase function at the periphery, but also suggests a 
lower rate of conversion from vitamin K1 in the knockout ani-
mals. Both WT and Abcc6-/- mice fed with high dose vitamin 
K1 diet had increased levels of both vitamin K1 and MK4 (Figs. 
5 and 6), indicating that the conversion of MK4 from vitamin 
K1 followed the increase in the availability of phylloquinone. 
However, although the high vitamin K1 diet induced a sig-
nificant increase in vitamin K1 serum concentration in Abcc6-/- 
mice, the increase was significantly less than the equiv-
alent serum K1 levels in control WT mice (Fig. 5). 
Figure 5. HpLC-MS analysis of serum levels of vitamin K1 from mice fed diets enriched with 5 or 100 mg/kg of vitamin K1. We measured a general, non-
significant increase in circulating vitamin K1 levels in the serum of both Wt and Abcc6-/- mice fed on a diet enriched with 5 mg/kg of vitamin K1. When 
fed with a diet enriched with 100 mg/kg vitamin K1, Wt mice had significantly more circulating vitamin K1 than the Abcc6-/- mice, with no significant 
increase in circulating vitamin K1 measured in Abcc6-/- mice fed with this diet.
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(2010).16 Along with the fact that the livers of the Abcc6-/- mice 
on the highest vitamin MK4 dose (but not the livers of the WT 
animals) were discolored and had an altered physical appearance 
leads us to infer that a reduced amount of vitamin K reaches the 
periphery, with a potential hepatic bottle neck. It is known that 
Abcc6 is present in the gut.33,34 If the transport from the gut is 
adversely affected by the loss of Abcc6 and therefore isn’t fully 
absorbed, and/or additional transport from the liver into the 
peripheral tissue would also be reduced leading to the observed 
changes in liver appearance. This hypothesis could be relatively 
easily explored using other routes of delivery to raise the vitamin 
K levels in the periphery, such as intravenous administration, but 
due to our results showing that inducing an increase in MK4 is 
possible in the Abcc6-/- mice (however not effective in treating the 
disease progression), it is not easily rationalized.
In summary, the results of the present study and those from 
Vanakker et al. (2010)16 both suggest a role of Abcc6 in vitamin 
K absorption, distribution or metabolism. However, our data also 
provided conclusive evidence that a dietary supplementation in 
vitamin K is not a viable approach to preventing PXE-related cal-
cification thus suggesting that the availability of vitamin K is not 
a limiting factor in the pathology of PXE and/or that vitamin 
This could imply several possibilities: first, the amount of cir-
culating vitamin K is not a factor in determining how much dif-
fuses from the blood and is available in the peripheral tissues for 
the carboxylation processes. Second, assuming the contrary, that 
the increased vitamin K is indeed available to the peripheral tis-
sues, the amount of vitamin K does not determine the rate of the 
carboxylation of the VKD inhibitors of mineralization in these 
mice. Third, the increased amount of MGP observed in the calci-
fied regions of the vibrissae is not concomitant to an increase in 
carboxylation activity by GGCX. Or lastly, MGP is not a major 
player in the pathogenesis of mineralization in this model, though 
this possibility appears less likely. Either way, the hypothesis that 
the “absence of ABCC6 in PXE prevents the liver from providing 
sufficient Vitamin K to the periphery” cannot be proven in our 
model.
Based on the discrepancy in MK4 serum levels between WT 
and Abcc6-/- mice fed on a normal diet and the lack of increase of 
MK4 serum levels in the vitamin K1 fed Abcc6-/- mice, which was 
most likely due to less K1 being available for conversion to MK4 
(Fig. 6), we suggest that Abcc6 might be involved in vitamin K 
transport, absorption or metabolism in the body, but only to a 
limited degree. This would be in agreement with Vanaker et al. 
Figure 6. HpLC-MS analysis of serum levels of vitamin MK4 from mice fed diets enriched with 5 or 100 mg/kg of vitamin K1. When fed with a normal 
diet the serum taken from Abcc6-/- mice had significantly less circulating MK4 than Wt controls. We measured a general, non-significant increase in 
circulating vitamin MK4 levels in the serum of Wt mice fed on a diet enriched with 100 mg/kg of vitamin K1. Wt mice fed with 100 mg/kg of vitamin K1 
from pre-onset had significantly more circulating MK4 than Abcc6-/- mice. there was no increase in circulating MK4 levels in the serum of Abcc6-/- mice 
fed on any of the vitamin K1 diets.
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maximal mineralization and to cover several treatment options 
for different developmental ages: (1) Vitamin K-enriched feeding 
from in utero to 4.5 months aimed to prevent calcification with 
the maximum time of increased vitamin K exposure. These mice 
were exposed to vitamin K in utero, breast-fed from vitamin K-fed 
mothers and then weaned on enriched vitamin K diets. Next, (2) 
by treating mice from weaning age at 3 weeks, which is before the 
onset of the phenotype (pre-onset), to 4.5 months old we sought 
to test whether the mineralization phenotype could be averted by 
exposing young mice to the diets. Finally, (3) mice were fed from 
3 months of age, which is after the onset of the phenotype (post-
onset) for 12 weeks. The latter experiment was designed to test 
whether treatment with the vitamin K diets could stop or possibly 
reverse calcification progression. This particular treatment regime 
is likely the most applicable as a potential treatment to the PXE 
condition since diagnosis is usually made after the phenotype has 
occurred.
Histochemisty and immunohistochemistry. Direct histologi-
cal visualization of calcium deposition following Alizarin red S 
staining on paraffin-embedded sections was carried out on the 
left muzzle skin of each mouse. Briefly, 5 μm slides were depar-
affinized and incubated in Alizarin red S solution (Sigma) for 5 
minutes, excess dye was removed with a 50% mixture of acetone 
K-dependent inhibition of calcification may not be as preponder-
ant in the development of this disease as previously thought.
Materials and Methods
Animals. C57BL/6J mice designated here as wild-type (WT) 
controls were purchased from Jackson laboratories. Abcc6-/- mice 
were obtained from the laboratory of Dr. J. Uitto at the Thomas 
Jefferson University23 via a standard UBMTA. Mice used in these 
study have been housed and cared for in an approved Animal Care 
facility in the BioScience Building of the University of Hawaii 
School of Medicine. The mice were kept under routine labora-
tory conditions with 12 hours light-dark cycle with access ad libi-
tum to water and standard chow. The Institutional Animal Care 
and Use Committee of the University of Hawaii approved this 
study. Experiments have been conducted according to national 
guidelines.
Diet. Abcc6-/- and WT mice were placed on a diet enriched 
with either 5 (low dose) or 100 mg/kg (high dose) of vitamin 
K1 (phylloquinone) or vitamin K2, specifically MK4. The specifi-
cally formulated diets were purchased from Bio-Serv, Inc., (AIN-
93M). We designed our vitamin K-enriched diet experiment to 
take place within the first 5 months of life during the phase of 
Figure 7. HpLC-MS analysis of serum levels of vitamin MK4 from mice fed diets enriched with 5 or 100 mg/kg of vitamin MK4. there was a significant 
increase in the levels of circulating MK4 in Wt mice fed with a diet enriched with either a 5 mg/kg or 100 mg/mg of MK4. Additionally, we measured 
significant increases in circulating MK4 in Abcc6-/- mice fed with 100 mg/kg of MK4 in both pre- and post-onset groups. there was no significant in-
crease in serum levels of MK4 in Abcc6-/- mice fed with the 5 mg/kg MK4 diet in either the pre- or post onset groups or in either of the in utero groups.
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colorimetric assay35 that measures directly the amount of cal-
cium within excised muzzle tissue, which is then corrected for 
tissue weight. Briefly, the entire skin from one side of the muzzle 
was harvested, minced and incubated at room temperature for 
48 hours in 0.15 N HCl. The total calcium content of the HCl 
supernatant was assessed by measuring the absorbance at 550 nm 
using the Calcium (CPC) Liquicolor kit (Stanbio). Calcium con-
tent was normalized to total tissue dry weight prior to mincing. 
The obtained absorbance values were quantified against a known 
standard to provide calcium concentration in mg per deciliter 
and per gram of tissue.
Blood analysis. Blood samples were harvested from each 
mouse and the serum was immediately separated by low-speed 
centrifugation and stored at -80°C until HPLC-MS analysis 
of total serum vitamin K1 and vitamin MK4 content could be 
performed. Vitamin K1 and K2 were extracted as described in 
Spronk et al. (2003),36 with some modifications. Briefly: 25 μl of 
plasma sample was diluted 1:1 with PBS. For deproteination, 200 
μl ethanol was added and vigorously vortexed. Vitamin Ks were 
extracted with 600 μl n-hexane. After one minute vortexing the 
samples were centrifuged (5 min at 1,000 rpm) and the hexane-
phase was separated and dried under a stream of nitrogen. The 
extracted material was dissolved in 50 μl isopropanol, and kept at 
-20°C until HPLC-MS analysis in sealed glass vials. For calibra-
tion purposes 0, 1, 5, 25 and 125 nM vitamin K1 and vitamin K2 
was added to WT mouse serum and the extraction was carried 
out in the same way.
Mass spectrometric measurements were run on an AB Sciex 
3200 QTrap tandem mass spectrometer. The components were 
ionized in negative ion mode using an atmospheric pressure 
chemical ionization (APCI) source. The instrument was scanned 
in multiple reaction-monitoring (MRM) mode. The MRM 
transition was 444/185 for MK4 and 450/185 for vitamin K1. 
The samples were separated prior to mass spectrometric analysis 
using a Perkin Elmer HPLC system. Mobile phases were: water 
and acetonitrile with a flow rate of 0.4 ml/min. A Phenomenex 
LUNA Phenyl-hexyl column (C18, 55 x 2 mm, 3 μm particle 
size) was used for the separation. The oven temperature was kept 
at 40°C.
Additionally, analysis of blood chemistry of treated and con-
trol mice was performed using the i-STAT EC8+ system (Abbott).
Statistical analysis. Data were analyzed with the statistical 
software PRISM® (GraphPad). Statistical analyses were per-
formed using two-tailed unpaired Student’s t-tests to determine 
statistical difference between WT and Abcc6-/- groups. Results 
were expressed as mean ± SEM and considered significant for p < 
0.05, *p < 0.05, **p < 0.01 ***p < 0.001.
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and xylene and the slides were mounted with Permount (Fisher 
Scientific). Selected sections from each treatment group were 
examined for calcium deposition and images were collected using 
an Axioscope 2 fluorescent microscope.
For immunofluorescent staining, muzzle skin samples were 
quickly harvested, placed in Optimum Cutting Temperature 
(OCT) compound and stored at -80°C. Immunofluorescent 
staining of whisker samples from high dose diets was performed 
using 5 μm-thick frozen sections. A mouse monoclonal anti-
ucMGP antibody (VitaK BV, Maastricht) was used to specifically 
detect the uncarboxylated MGP. A rabbit polyclonal anti-tMGP 
antibody (Santa Cruz biotech, Santa Cruz, CA) was used iden-
tify total MGP (carboxylated and uncarboxylated) while OC 
was visualized with a rabbit polyclonal antibody (Millipore, 
Temecula, CA). The secondary antibody was Alexafluor 488 
(Invitrogen, Carlsbad, CA). The distribution of MGP and OC 
in the capsule of the vibrissae was determined by imaging using 
an Axioscope 2 fluorescent microscope (Zeiss, Thornwood, NY). 
Individual images were collected and processed with Photoshop 
CS3 (Adobe, San Jose, CA).
Colorimetric measurement. To quantify the levels of min-
eral deposition in the different groups of mice we carried out a 
Figure 8. Immunofluorescent detection of MGp in the vibrissae’s cap-
sule of mice fed diets enriched with 100 mg/kg of vitamin K1 and MK4. 
Frozen serial sections from the muzzle tissue were used for both im-
munofluorescent and Alizarin S Red staining. We observed large posi-
tive staining of both ucMGp and tMGp (green) in the calcified regions 
of the vibrissae’s capsule of Abcc6-/- mice fed with normal or vitamin 
K-enriched diets (Arrows), suggesting that the carboxylation status of 
MGp in these tissues is unaffected by increased dietary vitamin K1 or 
MK4. the counterstaining on immunofluorescent images was obtained 
with propidium iodide. the scale bar represents 200 μm.
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